Among Jak inhibitors, allosteric Tyk2 inhibitors may be the most promising class for oral treatment of moderate to severe psoriasis, with the best efficacy/safety ratio and negligible changes in laboratory parameters. This evidence concerns the gene TYK2 and psoriasis.